BioAgeDiagnostics adds Dr. Charles Randquist to medical advisory board

BioAgeDiagnostics has appointed Dr. Charles Randquist to its Medical Advisory Board as the Denmark-based precision health company expands its longevity diagnostics strategy. The move is meant to strengthen the clinical side of its multi-omics approach to biological ageing and preventive medicine.

Why it matters: - BioAgeDiagnostics is trying to make longevity medicine more clinically usable, not just more measurable. - Dr. Charles Randquist adds long-term experience in aesthetic and reconstructive surgery, preventive health, regenerative medicine and longevity medicine. - The appointment is meant to strengthen the company’s push to translate biomarker data into personalized health decisions.

What happened: - BioAgeDiagnostics announced the appointment of Dr. Charles Randquist to its Medical Advisory Board on October 26, 2026. - The company is based in Charlottenlund, Denmark. - Dr. Randquist has 30 years of experience in aesthetic and reconstructive plastic surgery. - Dr. Randquist has 8 years of experience in preventive health, regenerative and longevity medicine. - Dr. Randquist founded Victoriakliniken and Dr.C-Health.

The details: - BioAgeDiagnostics focuses on advanced biological ageing diagnostics and measurable health outcomes. - The company said Dr. Randquist will contribute clinical perspective to its integrated, multi-omics approach to longevity medicine. - The diagnostic portfolio includes epigenetic ageing assessments, proteomic biomarkers, metabolic health, immune ageing, microbiome profiling and genetic insights. - The company says the goal is to build measurable baselines and track biomarker changes over time. - BioAgeDiagnostics positions biological ageing as a complex process that spans molecular, cellular and physiological systems. - The company says advances in epigenetics, proteomics, metabolomics and other biomarker technologies are creating new ways to characterize ageing, but clinical interpretation remains a challenge. - The company’s portfolio also spans genomics, epigenetics, proteomics, metabolomics, immune ageing, microbiome analysis and clinical biomarkers. - BioAgeDiagnostics says its framework is designed to help healthcare professionals operationalize and scale longevity medicine. - The company says its model combines advanced diagnostics, longevity therapeutics, clinical protocols and integrated operational infrastructure.

Between the lines: - The advisory board hire suggests BioAgeDiagnostics is leaning harder into clinical credibility as precision longevity diagnostics moves closer to routine care. - The company is signaling that biomarker readings alone are not enough; interpretation, medical context and follow-up matter. - Bettina, co-founder and managing partner, said the company wants precision longevity medicine to be actionable, measurable and scalable. - The company also stresses the difference between biomarker changes and proven clinical outcomes, which matters in a field where scientific promise can run ahead of validation.

What's next: - Dr. Randquist will help guide BioAgeDiagnostics as it develops its longevity medicine platform. - BioAgeDiagnostics says it will continue building scientific and clinical expertise to support responsible adoption of precision longevity diagnostics. - The company is also focusing on longitudinal measurement to see whether personalized interventions improve health over time. - BioAgeDiagnostics says the next step is helping clinicians identify earlier prevention opportunities and tailor interventions to individual patients.

The bottom line: - BioAgeDiagnostics is using a high-profile clinical appointment to reinforce its pitch that longevity diagnostics must be both scientifically advanced and clinically useful.